Moleculin Announces Confirmatory In Vitro Analysis of WP1122

HOUSTON, June 16, 2020 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that a repeat of previous in vitro testing has corroborated the antiviral potential of WP1122.

The release as fetched from its publisher. moleculin.com ↗